Earnings ·
Reports Q3 net loss of $59.5M; bitopertin Phase 3 APOLLO trial meets all endpoints
IRONDisc Medicine, Inc.
Disc Medicine reported a third-quarter net loss of $59.5 million, narrowing from $62.3 million in the prior-year period, driven by lower research and development expenses that fell to $44.1 million from $50.3 million. The company highlighted positive Phase 3 APOLLO trial results for bitopertin in erythropoietic protoporphyria (EPP), which met all primary and secondary endpoints, including a 41.4% reduction in whole-blood metal-free PPIX. Disc plans to resubmit the New Drug Application by year-end with an FDA decision expected by mid-2027. The firm ended Q3 with $682.8 million in cash and marketable securities, bolstered by a $485.9 million public offering completed in October 2026 that extends its cash runway into 2030. Disc Medicine is a clinical-stage biopharmaceutical company focused on discovering and developing novel treatments for serious hematologic diseases.